Substance and claimed effects

Hidradenitis suppurativa (HS), also called acne inversa, is a chronic relapsing inflammatory skin disease centred on hair-follicle units in intertriginous skin: axillae, groin, perianal/perineal area, buttocks, inframammary fold. Clinical hallmarks are recurrent painful inflammatory nodules and abscesses (Hurley stage I); recurrent abscesses with sinus tracts and scarring (stage II); and diffuse interconnected sinus tracts, draining tunnels and extensive scarring across an entire anatomic region (stage III) Sabat 2020. The condition is not contagious, not primarily infectious, and not a hygiene problem — it is a primary disorder of innate immune dysregulation around occluded hair follicles Wolk 2020.

Claimed effects this entry covers holistically: dermatologic disease control (lesion count, flare frequency, draining tunnels), pain, scarring trajectory and visible skin damage over years, mental-health comorbidity (depression, anxiety, suicidality), cardiometabolic comorbidity and all-cause mortality, sleep disruption from nocturnal pain, energy and focus cost from chronic inflammation and chronic pain, and the diagnostic-delay penalty of an average 7–10 years from symptom onset to diagnosis Saunte 2015. Modern medical management — long-course antibiotics, hormonal adjuncts, and TNF-α / IL-17 biologics (adalimumab, secukinumab, bimekizumab) — alongside selective surgery substantially changes every one of those trajectories Kimball 2016 Kimball 2023 Kimball 2024.

Evidence by addressing question

mechanism

Science / mechanism. The primary pathogenic event is follicular occlusion of the folliculopilosebaceous unit, not apocrine-gland infection (the discarded 20th-century model). Infundibular hyperkeratosis and follicular plugging precede follicular rupture; ruptured keratin, cellular debris and commensal flora spill into the perifollicular dermis and trigger an innate immune cascade dominated by IL-1β, TNF-α, and the IL-17 / IL-23 / Th17 axis, with neutrophil-rich abscess formation and downstream draining sinus tracts that epithelialise and become permanent anatomical features Wolk 2020 Sabat 2020. Th17 dominance is the mechanistic rationale for IL-17A / IL-17A+F blockade (secukinumab, bimekizumab); TNF-α elevation is the rationale for adalimumab. Smoking and obesity are the dominant non-genetic risk modifiers — meta-analysis pooled OR ~3.10 for smoking and ~2.48 for obesity — likely through follicular and microbiomic effects rather than primary autoimmune triggering. Genetic contribution is real but heterogeneous: γ-secretase complex mutations (NCSTN, PSEN1, PSENEN) explain a minority of familial cases; most disease is polygenic with strong gene-environment interaction.

Practice / clinical consensus. The shift from "infected sweat glands" to "follicular-occlusion immune disease" is now consensus across North American (USCHSF/CHSF) and European (EHSF, EuroGuiDerm) guideline bodies Alikhan 2019a. Antibiotic regimens (notably clindamycin–rifampicin) act partly as anti-inflammatories, not purely as antimicrobials — supporting the immune-disease model.

evidence

Adalimumab (TNF-α blockade). PIONEER I and II were twin Phase 3 placebo-controlled RCTs (n=633 combined) of weekly subcutaneous adalimumab 40 mg in moderate-to-severe HS. The primary endpoint, HiSCR (≥50% reduction in abscess + inflammatory nodule count, no increase in abscess or draining-fistula counts) at week 12, was met: PIONEER I 41.8% vs 26.0% placebo; PIONEER II 58.9% vs 27.6% placebo Kimball 2016. This led to FDA approval in 2015 — the first ever approved systemic therapy for HS.

Secukinumab (IL-17A blockade). SUNSHINE and SUNRISE (n≈1,084 combined, 40 countries) tested secukinumab 300 mg subcutaneously every 2 weeks vs every 4 weeks vs placebo through week 16, with continuation to week 52. HiSCR at week 16 was met for the every-2-week arm in both trials (SUNSHINE 45% vs 34% placebo; SUNRISE 42% vs 31% placebo) with sustained or improved response at week 52 and a favourable safety profile Kimball 2023. FDA-approved for moderate-to-severe HS in October 2023.

Bimekizumab (IL-17A + IL-17F dual blockade). BE HEARD I and II (n=1,014 combined, 48 weeks) showed HiSCR50 at week 16 of ~48–52% with bimekizumab vs ~29–32% placebo, and HiSCR75 ~32–34% vs ~12–14% — the deepest responses yet demonstrated in HS RCTs, with rapid onset (significant separation by week 4) and durability through 48 weeks Kimball 2024. Pain responses were substantial: at week 48, 56–64% of patients rated their skin pain as "much better." FDA-approved May 2024.

Antibiotics. Clindamycin 300 mg twice daily + rifampicin 600 mg daily for 10–12 weeks remains a workhorse for moderate disease — supported by Gener's 116-patient retrospective series showing significant Sartorius-score improvement Gener 2009 and a 283-patient prospective European cohort showing comparable HiSCR (~48%) to tetracycline monotherapy Alikhan 2019b. The evidence base is heterogeneous (mostly retrospective, mixed Hurley severity) but the regimen sits in every modern guideline.

Surgery. Systematic review of 22 studies: pooled recurrence ~13% for wide local excision (best with flap or graft closure: 6–8%), ~22% for local excision, ~27% for deroofing — though deroofing is tissue-sparing and tracts within an anatomic region can be picked off individually Mehdizadeh 2015. Surgery does not cure HS — new lesions arise in previously unaffected skin — but for Hurley III disease, wide excision is often the only intervention that durably controls established tunnels.

Comorbidity-modifying evidence. Adalimumab reduced systemic inflammation markers in PIONEER follow-up analyses, plausibly translating to cardiovascular risk reduction — though hard-endpoint CV trials in HS do not yet exist. Bariatric weight loss ≥15% and GLP-1 receptor agonists (semaglutide, tirzepatide) show emerging benefit on HS severity in observational and small cohort studies Jørgensen 2024.

protocol

Practice / clinical consensus. Treatment is stratified by Hurley stage and disease activity, per North American and European guidelines Alikhan 2019a Alikhan 2019b. Foundation layer (all stages): smoking cessation, weight optimisation if BMI elevated, topical clindamycin 1% solution for mild localised disease, intralesional triamcinolone (5–10 mg/mL) for acute painful nodules, daily chlorhexidine or antiseptic wash. Stage I–II active disease: oral tetracyclines (doxycycline 100 mg twice daily × 12 weeks) or clindamycin 300 mg twice daily + rifampicin 600 mg daily × 10–12 weeks; hormonal adjuncts in female patients (spironolactone 100–200 mg/day, combined OCP, metformin if insulin resistance). Stage II–III or treatment-refractory: biologic therapy. Adalimumab 160 mg week 0, 80 mg week 2, then 40 mg weekly maintenance Kimball 2016. Secukinumab 300 mg every 2 weeks after a loading schedule Kimball 2023. Bimekizumab 320 mg every 2 weeks for 16 weeks then every 4 weeks Kimball 2024. Surgical adjuncts (deroofing of focal tunnels, wide excision of tunnel networks) integrated alongside biologic therapy in Hurley III. Pain management with NSAIDs, neuropathic-pain adjuncts (gabapentin, duloxetine) for chronic-pain phenotype; opioid avoidance is the standard given long disease horizon.

contraindications

Practice. TNF-α and IL-17 biologic contraindications largely follow the labels validated in their primary indications (psoriasis, ankylosing spondylitis, IBD) Alikhan 2019b. Adalimumab: active serious infection including untreated latent tuberculosis (TB screening mandatory before initiation), moderate-to-severe heart failure (NYHA III/IV — adalimumab can worsen heart failure), demyelinating disease, active malignancy within 5 years (relative). IL-17 inhibitors (secukinumab, bimekizumab): active Candida infection (increased mucocutaneous candidiasis on therapy), active TB, inflammatory bowel disease (IL-17 blockade can paradoxically flare IBD — relative contraindication). Pregnancy: adalimumab has the largest reassuring safety dataset of the three and is the preferred biologic if therapy is needed during pregnancy; IL-17 inhibitors have less data and are typically held. Live vaccines contraindicated during therapy. Hepatitis B/C screening required before any biologic initiation. Clindamycin–rifampicin: rifampicin is a potent CYP3A4 inducer — major interactions with hormonal contraceptives (reduced efficacy — backup contraception required), warfarin, many antiretrovirals, tacrolimus, statins.

misconceptions

The most common and most damaging misconception — held by patients and generalist clinicians — is that HS lesions are infected sweat glands or boils caused by poor hygiene, sexual activity, or shaving practice. This drives the average 7–10 year diagnostic delay, repeated futile incision-and-drainage procedures, repeated short antibiotic courses for "recurrent furunculosis," and the corrosive patient shame that suppresses care-seeking Saunte 2015. The mechanism is follicular-occlusion immune disease, not infection (cultures are frequently sterile or grow commensals) and not a hygiene failure (the most fastidious patients still flare) Wolk 2020. Second misconception: that HS is a self-limiting condition that "burns out" in midlife. Population studies suggest persistence into the 4th–6th decade for most patients; remission is not the rule. Third: that biologics are a last resort. Modern guideline thinking has shifted toward earlier biologic initiation for moderate disease to prevent tunnel formation and permanent scarring, which are largely irreversible once established Alikhan 2019b.

audience

Population variability. Sex ratio in North American and European cohorts is ~3:1 female-to-male, reaching ~4:1 in some US datasets; East Asian (South Korea, Japan) cohorts show male predominance Garg 2017. African-American patients in US data carry the highest prevalence (~296 per 100,000 vs ~98 per 100,000 overall) Garg 2017. Onset peaks in the late teens through 30s; pediatric and post-menopausal onset both occur but are less common. Pregnancy: roughly one-third of patients improve, one-third worsen, one-third unchanged; postpartum often sees flare. Men: less prevalent overall but more likely to have genital/perineal involvement and severe (Hurley III) disease at presentation.

alternatives

Lifestyle adjuncts with reasonable evidence: smoking cessation (every guideline lists it; magnitude of HS-specific benefit is hard to quantify from observational data but the directional signal is consistent) Tzellos 2015; weight loss in patients with elevated BMI (bariatric studies show ≥15% weight loss → significant HS-severity improvement); zinc gluconate 90 mg/day (modest evidence, low-risk adjunct); dietary trials (low glycaemic / dairy elimination) with case-series-level evidence only. Hormonal options in women: spironolactone, OCP, finasteride, metformin — all guideline-listed as second-line options based on retrospective and small prospective data Alikhan 2019b. Older systemic agents pushed aside by biologics: isotretinoin (poor efficacy in HS — different from acne), oral retinoids (acitretin, modest), cyclosporin (some response in refractory cases), dapsone. Investigational pipeline: JAK inhibitors (upadacitinib, povorcitinib), IL-1 axis inhibitors, complement-pathway agents — Phase 2 and Phase 3 readouts ongoing.

failure-modes

The dominant failure mode is the 7–10 year diagnostic delay itself — during which patients accumulate permanent sinus tracts and scarring that no medical therapy can later reverse Saunte 2015. Patients consult on average more than three different physicians (GPs, dermatologists, surgeons, gynaecologists) and accumulate more than three misdiagnoses before correct attribution; longer delay correlates with worse Hurley stage and more comorbidities at diagnosis. Second failure mode: repeated incision-and-drainage of recurrent abscesses without instituting disease-modifying therapy — temporary relief, no change in trajectory, accumulating scar burden. Third: under-dosing or premature discontinuation of biologics — HS biologic doses are higher than the psoriasis labels (adalimumab 40 mg weekly, not every-other-week) and response is often slower (assessed at week 12–16); patients and clinicians who calibrate to psoriasis expectations stop too early. Fourth: ignoring comorbidity screening — HS patients have substantially elevated cardiovascular event and mortality risk (Egeberg's Danish cohort: HR 1.57 for MI, 1.33 for ischaemic stroke, 1.95 for CV death, 1.35 for all-cause mortality) Egeberg 2016 and the depression/suicidality burden is severe; treating only the skin misses the systemic-disease frame.

practicalities

Specialist access is the rate-limiting reality. The diagnosis is made by a dermatologist (often an HS-specialty clinic in academic centres); generalist mis-recognition is the headline reason for the diagnostic delay. Biologics are administered as subcutaneous injections at home after training. Cost without insurance is prohibitive: adalimumab US list price ~$70,000/year (biosimilars now available, ~30–50% lower), secukinumab and bimekizumab in similar tier. With US commercial insurance plus manufacturer copay assistance, out-of-pocket can drop to under $10/month for eligible patients; Medicare/Medicaid coverage variable and step-therapy requirements common (typically fail conventional therapy first). Outside the US, single-payer systems generally cover after failure of conventional therapy. Monitoring labs: TB screening (interferon-gamma release assay) before initiation, hepatitis serology, periodic CBC and liver panels.

stakes

Untreated or undertreated HS over 7–10 years of diagnostic delay tends to one trajectory: progression from isolated tender nodules in Hurley I, to recurrent abscesses and developing sinus tracts in Hurley II, to confluent draining tunnels and disfiguring scarring in Hurley III Sabat 2020. Once tunnels epithelialise they are permanent — medical therapy quiets inflammation around them but does not collapse the tunnel, which is why early intervention matters disproportionately. Quality-of-life impact ranks among the highest of any skin disease — pain is the most-reported symptom (mean NRS ~4, max-week NRS often 7–10 during flares) and correlates strongly with reduced QoL on Skindex-16 and DLQI scales. Depression prevalence ~21% (vs ~8% general population, OR 2.06), anxiety ~19% (OR 1.91), and suicide OR ~1.56 in meta-analytic data; the depression burden scales with Hurley stage (~35% in Hurley III) Machado 2019 Patel 2020 Phan 2020. Cardiovascular and metabolic comorbidity is substantial and reflects shared inflammatory drivers plus shared risk factors (smoking, obesity, insulin resistance): elevated risk of MI, stroke, cardiovascular death, and all-cause mortality in large registry data Egeberg 2016 Tzellos 2015.

payoff

Modern biologic therapy changes the trajectory measurably. With adalimumab, ~42–59% of patients achieve HiSCR (≥50% reduction in inflammatory lesion count) by week 12 Kimball 2016; with secukinumab Q2W, similar ~42–45% HiSCR at week 16 sustained through week 52 Kimball 2023; with bimekizumab, HiSCR50 ~48–52% and HiSCR75 ~32–34% at week 16, sustained to week 48 Kimball 2024. Pain — the symptom most tied to QoL — improves substantially across biologic classes; in BE HEARD, the majority of patients rated skin pain as "much better" by week 48 and the proportion rating their pain as "severe" dropped from ~30% at baseline to ~5%. Onset of meaningful response is weeks-to-months, not days; the durability question (5- to 10-year disease-modification) is being answered in open-label extensions and registries. Mental-health comorbidity may improve as inflammation and pain remit, but this is correlated rather than RCT-proven. Early treatment before tunnel formation is the strongest payoff lever and the one most lost to diagnostic delay.

out-of-scope

Adjacent topics this entry signposts but does not cover end-to-end: acne vulgaris (different folliculopilosebaceous disease, different management); pilonidal disease (overlapping anatomic distribution but distinct pathogenesis); Crohn's disease and IBD (genuine HS-IBD co-occurrence — share IL-23/Th17 biology); psoriasis (also TNF/IL-17 responsive; readers with HS may have additional psoriasis). Smoking cessation as a standalone substance; weight management and GLP-1 receptor agonists; dermatology access (general).

The credibility range

Optimist case. HS is now a treatable chronic inflammatory disease on the same medicinal footing as psoriasis or rheumatoid arthritis. Three FDA-approved biologic classes (TNF-α, IL-17A, IL-17A+F) all demonstrate replicated Phase 3 efficacy with rapid, durable responses and acceptable safety profiles Kimball 2016 Kimball 2023 Kimball 2024. The pathogenesis is mechanistically resolved (follicular occlusion → innate immune cascade → Th17 dominance), explaining why each biologic class works and predicting which next-generation agents (JAK inhibitors, IL-1 axis blockers) should work too. Treatment access via biosimilars and copay assistance has improved costs meaningfully in the past 5 years. The patient-side problem is no longer "no treatment exists" but "diagnostic delay and referral failure prevent patients from reaching treatment" — a solvable problem of clinician and patient awareness.

Skeptic case. HiSCR50 — the standard primary endpoint — is a modest bar: a 50% reduction in inflammatory lesions, not remission. Across all three biologic classes the placebo-adjusted response rate is ~15–25 percentage points, with absolute responder rates of ~40–60% — meaning ~40–60% of patients on the most modern, expensive therapies do not achieve even this modest endpoint at week 12–16. Long-term durability beyond 1–2 years is reported mostly from open-label extensions and registries; head-to-head biologic-vs-biologic data are absent. Surgery rates remain high even with biologics — tunnels do not resolve medically. Comorbidities (cardiovascular, mortality, mental health) are pulled from observational data with substantial confounding by smoking, obesity, and socioeconomic status; the causal contribution of HS-specific inflammation to MACE/mortality is plausible but not RCT-proven. Diagnostic delay has been documented for two decades without measurable improvement.

Author's call. The article lands optimist-leaning: the substantive change in the past decade — from "incurable disease no one understands" to "chronic immune disease with three FDA-approved biologic classes and a defined mechanistic frame" — is real and underweighted in lay coverage. The two honest qualifiers carried throughout: (1) ~40–60% of biologic recipients still fall short of HiSCR50 at primary-endpoint timepoints, so the framing is "treatable, not curable, and durably manageable for the majority"; (2) the diagnostic-delay problem dominates outcomes more than the treatment-efficacy gap. The reader's highest-leverage action is recognition and dermatology access, not picking the right biologic.

Stakeholder and incentive map

• Commercial. AbbVie (adalimumab/Humira and biosimilars — first-mover advantage, IP cliff passed, biosimilar competition active), Novartis (secukinumab/Cosentyx), UCB (bimekizumab/Bimzelx). All three sponsored their pivotal Phase 3 trials. Investigational-stage: AbbVie (upadacitinib JAK), Incyte (povorcitinib), Boehringer (spesolimab IL-36).
• Professional. US Hidradenitis Suppurativa Foundation (USCHSF), Canadian HSF, European HS Foundation (EHSF) — issue guidelines, run annual symposia, advocate for diagnostic recognition and access. Strongly aligned with patient interest; modestly industry-funded.
• Patient/community. Active advocacy organisations (HS Connect, HS Heroes, Hope for HS) push diagnostic recognition, insurance access, and research funding. Reddit r/Hidradenitis and similar forums are large (~50K subscribers) and surface the lived experience — delays, misdiagnoses, copay-assistance navigation, biologic-switching journeys — that complement formal literature.
• Counter / friction. Insurance step-therapy requirements (fail antibiotics first) delay biologic initiation. Primary-care under-recognition is the dominant friction. No serious skeptical or anti-biologic camp exists comparable to other disease areas — the controversy is essentially absent because the unmet need is so visible.

Population variability

• Sex. Female-to-male ~3:1 in Western cohorts (4:1 in some US datasets); male predominance in East Asian cohorts Garg 2017. Men have higher rates of severe (Hurley III) and genital/perineal disease at presentation.
• Race/ethnicity. US population data show ~3-fold higher prevalence in African-American patients vs white patients (296 vs ~95 per 100,000); biracial patients also elevated Garg 2017. Diagnostic delay is longer in non-white patients; access disparities documented.
• Age. Onset most commonly second to third decade (late teens to 30s); pediatric onset associated with higher familial loading and faster progression; post-menopausal onset less common and often milder.
• Pregnancy. Variable — roughly one-third improve, one-third worsen, one-third unchanged; postpartum flare common. Adalimumab is the preferred biologic in pregnancy when therapy needed.
• Smoking/BMI status. Strong modifiers — non-smokers and patients at lower BMI tend to milder disease and better treatment response; smoking-cessation and weight optimisation are guideline-strength adjuncts Tzellos 2015.
• Genetic loading. Familial HS (γ-secretase mutations: NCSTN, PSEN1, PSENEN) accounts for ~5% of cases and tends to earlier, more severe, more widely distributed disease.

Knowledge gaps

• No head-to-head biologic RCTs. Treatment selection is currently driven by patient factors (pregnancy, IBD history, prior response) rather than comparative efficacy data.
• Long-term (5–10 year) outcomes of early biologic intervention vs delayed initiation: does early biologic therapy in Hurley I–II disease prevent progression to tunnel-burdened Hurley III? Mechanistically expected; not RCT-proven.
• Causal contribution of HS-specific inflammation to cardiovascular mortality, independent of shared risk factors (smoking, obesity). Whether biologic therapy reduces MACE in HS is an open question; downstream from PIONEER inflammation-marker analyses but not endpoint-tested.
• Mechanistic role of the cutaneous microbiome and whether targeted microbiome interventions add to immune-blockade therapy.
• Why women in the West are 3–4× more affected but East Asian cohorts show male predominance — hormonal, genetic, and ascertainment-bias explanations all live.
• Diagnostic-delay interventions that work at scale. The problem has been documented for 20+ years without measurable improvement; primary-care education, patient-facing recognition tools, and AI-assisted dermatology triage are all unproven.
• Predictors of biologic response. ~40–60% of patients fall short of HiSCR50 on every approved biologic; no validated biomarker selects responders prospectively.

Scope vs brief. The brief named recurrent painful nodules, scarring, sinus tracts, mental health, diagnostic delay, and modern medical and biologic treatments. All six are covered end-to-end. No narrowing.

Action and cadence calls. Picked decide over know because the entry's payoff is reaching a dermatologist and choosing a treatment path — not just recognition. Picked as-needed cadence because the reader's action is trigger-based on symptom recognition; once on therapy, the cadence is daily/weekly, but that's the treatment's cadence, not the entry's.

Contraindications token left empty. The entry's recommendation is "see a dermatologist and decide on treatment with them," which is safe for every reader. Biologic-specific contraindications (advanced heart failure for anti-TNF, active IBD for anti-IL-17, pregnancy nuances) live in the contraindications section's warning callout and are the clinician's call; flagging the entry itself as unsafe for those groups would mislead.

Audience left unscoped. Female-to-male prevalence is ~3:1 in Western cohorts and the temptation was to scope audience.gender to female. Did not, because men with HS often present with more severe Hurley III and genital/perineal disease, and recognition equally matters for them. Onset peaks 18–39 but the disease persists through 40–59 in most patients, so age scoping would have mis-narrowed too.

Rating difficulties.

• cost_burden: tension between $50–70K U.S. list and sub-$100/month real out-of-pocket for many insured patients. Landed at 4 (major) as the honest middle; without coverage the score would be 5.
• longevity: registry data show large hazard ratios for MI, CV death, all-cause mortality (Egeberg 2016) but treatment-effect on hard endpoints is not RCT-proven. Score 3 reflects "meaningful, mechanistically expected, not yet endpoint-tested."
• evidence: held at 4 rather than 5 because three Phase 3 programmes are strong but no head-to-head trials exist and HiSCR50 responder rates are 40–60% (modest by inflammatory-skin-disease standards).

Future-link candidates (to wire in once they exist): smoking cessation as a standalone entry; GLP-1 receptor agonists (semaglutide, tirzepatide) and weight management; inflammatory bowel disease; dermatology access. The out-of-scope section signposts these but does not anchor them.

Separate-entry candidates. None flagged inside HS. The adjacent topics above are independent entries in their own right, not branches of this one.